St. Jude Medical Inc Valuation – June 2016 $STJ

Benjamin Graham taught that Intelligent Investors must do a thorough fundamental analysis of investment opportunities to determine their intrinsic value and inherent risk.  This is best done by utilizing a systematic approach to analysis that will provide investors with a sense of how a specific company compares to another company or by reviewing the 10 Companies Benjamin Graham Would Invest In Today - June 2016.  By using the ModernGraham method one can review a company’s historical accomplishments and determine an intrinsic value that can be compared across industries.  What follows is a stock analysis showing a specific look at how St. Jude Medical Inc (STJ) fares in the ModernGraham valuation model.

Company Profile (obtained from Google Finance): St. Jude Medical, Inc. is focused on the development, manufacture and distribution of cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas, and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders. The Company’s product categories include tachycardia implantable cardioverter defibrillator systems; atrial fibrillation products (electrophysiology introducers and catheters, advanced cardiac mapping, navigation and recording systems and ablation systems); bradycardia pacemaker systems; vascular products (vascular closure products, pressure measurement guidewires, optical coherence tomography imaging products, vascular plugs, heart failure monitoring devices and other vascular accessories); structural heart products (heart valve replacement and repair products and structural heart defect devices); neuromodulation products, and Thoratec products.


To read the details of this valuation, you must be logged in as a premium member. If you are not a premium member, please consider becoming one.

Premium members can view a full ModernGraham valuation of the company and have access to download a PDF version of the valuation for easy reference. Here is a free sample valuation pdf, and here is a post detailing what can be found within each individual company’s valuation.


Downloadable PDF version of this valuation:

ModernGraham Valuation of STJ – June 2016

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

What kind of Intelligent Investor are you?

Defensive Investor; must pass 6 out of the following 7 tests.
1. Adequate Size of the Enterprise Market Cap > $2Bil $21,546,316,703 Pass
2. Sufficiently Strong Financial Condition Current Ratio > 2 1.72 Fail
3. Earnings Stability Positive EPS for 10 years prior Pass
4. Dividend Record Dividend Payments for 10 years prior Fail
5. Earnings Growth Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end 112.73% Pass
6. Moderate PEmg Ratio PEmg < 20 22.95 Fail
7. Moderate Price to Assets PB Ratio < 2.5 OR PB*PEmg < 50 5.35 Fail
Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.
1. Sufficiently Strong Financial Condition Current Ratio > 1.5 1.72 Pass
2. Sufficiently Strong Financial Condition Debt to NCA < 1.1 4.77 Fail
3. Earnings Stability Positive EPS for 5 years prior Pass
4. Dividend Record Currently Pays Dividend Pass
5. Earnings Growth EPSmg greater than 5 years ago Pass

Stage 2: Determination of Intrinsic Value

STJ value chart June 2016

EPSmg $3.34
MG Growth Estimate 5.90%
MG Value $67.73
Opinion Overvalued
MG Grade C
MG Value based on 3% Growth $48.36
MG Value based on 0% Growth $28.35
Market Implied Growth Rate 7.23%
Current Price $76.55
% of Intrinsic Value 113.02%

St. Jude Medical, Inc. is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, poor dividend history, and the high PEmg and PB ratios. The Enterprising Investor is only concerned with the level of debt relative to the net current assets. As a result, all Enterprising Investors following the ModernGraham approach should feel comfortable proceeding with the analysis.

As for a valuation, the company appears to be Overvalued after growing its EPSmg (normalized earnings) from $2.39 in 2012 to an estimated $3.34 for 2016. This level of demonstrated earnings growth does not support the market’s implied estimate of 7.23% annual earnings growth over the next 7-10 years. As a result, the ModernGraham valuation model, based on Benjamin Graham’s formula, returns an estimate of intrinsic value below the price.

St. Jude Medical, Inc. receives an average overall rating in the ModernGraham grading system, scoring a C.

Stage 3: Information for Further Research

STJ charts June 2016

Net Current Asset Value (NCAV) -$19.73
Graham Number $36.06
PEmg 22.95
Current Ratio 1.72
PB Ratio 5.35
Current Dividend $1.18
Dividend Yield 1.54%
Number of Consecutive Years of Dividend Growth 6


Useful Links:

ModernGraham tagged articles Morningstar
Google Finance MSN Money
Yahoo Finance Seeking Alpha
GuruFocus SEC Filings

Most Recent Balance Sheet Figures

Balance Sheet Information 3/1/2016
Total Current Assets $2,803,000,000
Total Current Liabilities $1,630,000,000
Long-Term Debt $5,591,000,000
Total Assets $12,552,000,000
Intangible Assets $7,864,000,000
Total Liabilities $8,453,000,000
Shares Outstanding (Diluted Average) 286,400,000

Earnings Per Share History

Next Fiscal Year Estimate $4.00
Dec2015 $3.07
Dec2014 $3.46
Dec2013 $2.49
Dec2012 $2.39
Dec2011 $2.52
Dec2010 $2.75
Dec2009 $2.26
Dec2008 $1.10
Dec2007 $1.59
Dec2006 $1.47
Dec2005 $1.04
Dec2004 $1.10
Dec2003 $0.92
Dec2002 $0.76
Dec2001 $0.48
Dec2000 $0.38
Dec1999 $0.07
Dec1998 $0.38
Dec1997 $0.15
Dec1996 $0.28

Earnings Per Share – ModernGraham History

Next Fiscal Year Estimate $3.34
Dec2015 $2.93
Dec2014 $2.81
Dec2013 $2.49
Dec2012 $2.39
Dec2011 $2.28
Dec2010 $2.05
Dec2009 $1.63
Dec2008 $1.30
Dec2007 $1.34
Dec2006 $1.16
Dec2005 $0.96
Dec2004 $0.85
Dec2003 $0.66
Dec2002 $0.49
Dec2001 $0.34
Dec2000 $0.26

Recommended Reading:

Other ModernGraham posts about the company

40 Companies in the Spotlight This Week – 2/21/15
St. Jude Medical Inc. Annual Valuation – 2015 $STJ
30 Companies in the Spotlight This Week – 11/15/14
St. Jude Medical Inc. Quarterly Valuation – November 2014 $STJ

Other ModernGraham posts about related companies

Zimmer Biomet Holdings Inc Valuation – June 2016 $ZBH
Waters Corporation Valuation – May 2016 $WAT
Align Technology Inc Valuation – May 2016 $ALGN
C.R. Bard Inc Stock Valuation – February 2016 $BCR
Psychemedics Corp Stock Valuation – February 2016 $PMD
Patterson Companies Inc Stock Valuation – February 2016 $PDCO
Edwards Lifesciences Corp Valuation – February 2016 $EW
Baxter International Inc Valuation – February 2016 $BAX
Cerner Corporation Valuation – February 2016 Update $CERN
Henry Schein Inc Valuation – February 2016 Update $HSIC


The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please be sure to review our detailed disclaimer.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.